Biodesix Inc: director chairman John Patience exercised 1,360 shares

What happened

• John Patience, director and chairman, exercised or converted derivative awards that resulted in the acquisition of 1,360 shares on Sep 30, 2026 (price listed as N/A).
• The filing also shows a disposition of 1,360 shares on Sep 30, 2026 at $0.00 for total $0 (reported as a derivative transaction).

Key details

• Transaction date(s) and price(s): Sep 30, 2026; acquisition line price N/A, disposition price $0.00 for total $0.
• Shares owned after the transaction: not reported in the filing.
• Relevant footnotes:
  • F1: each restricted stock unit (RSU) represents a contingent right to one share of common stock.
  • F4: these RSUs vest in four substantially equal installments on Mar 31, 2026; Jun 30, 2026; Sep 30, 2026; and Dec 31, 2026, generally subject to continued service, and have no expiration date.
  • F2: the reporting person is the sole general partner of Patience Enterprises LP and disclaims beneficial ownership except to the extent of pecuniary interest.
  • F3: the reporting person is the sole trustee of John Patience Living Trust (Jul 23, 1993).
• Form 4 filing date: Oct 2, 2026.

Why it may matter

• The filing reports a derivative conversion/exercise (code M) and a contemporaneous disposition of the same number of shares at $0.00.
• The transaction involved RSUs that vested on Sep 30, 2026 per the filing (see F1 and F4).
• A filing does not show why the insider traded or why the company acted.